Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
Leaders of the Arkansas Venture Center and the Little Rock Technology Park will set up offices in the former ARK Challenge space on the ground floor of the Block 2 building in the 100 block of East Markham in downtown Little Rock.
The Arkansas Research Alliance announced Wednesday that it has been awarded a $1.2 million contract from the U.S. Food and Drug Administration that will extend a collaborative research program focused on graphene-based nanomaterials.
The Arkansas Science and Technology Authority has awarded a $37,000 grant for a University of Arkansas at Little Rock biology professor who says nanomaterials could increase the germination rate and biomass yield of bioenergy crops.
The Arkansas Venture Center introduced its first class of Pre-Flight graduates Tuesday night with promising, early-stage startups pitching ideas developed over the course of a 14-week, pre-accelerator program. Pre-Flight is a program created by the Nashville Entrepreneur Center in 2011 and licensed this year by the AVC in Little Rock.